Impact of advanced age on management and prognosis in atrial fibrillation: Insights from a population-based study in general practice

Age and Ageing

Volumn 44, Issue 5, 2015, Pages 874-878

  Wolff, Andreas ^a   Shantsila, Eduard ^b   Lip, Gregory Y H ^b   Lane, Deirdre A ^b  

^a Chilliwack General Hospital   (Canada)

^b UNIVERSITY OF BIRMINGHAM   (United Kingdom)

Author keywords

Age; Antithrombotic therapy; Atrial fibrillation; General practice; Older people; Stroke

Indexed keywords

ANTICOAGULANT AGENT; ANTITHROMBOCYTIC AGENT; FIBRINOLYTIC AGENT;

ADULT; AGED; ANTICOAGULATION; ARTICLE; ATRIAL FIBRILLATION; CAUSE OF DEATH; CEREBROVASCULAR ACCIDENT; COHORT ANALYSIS; CONTROLLED STUDY; FEMALE; FOLLOW UP; GENERAL PRACTICE; HUMAN; INCIDENCE; MAJOR CLINICAL STUDY; MALE; MORTALITY; OBSERVATIONAL STUDY; PRIORITY JOURNAL; RETROSPECTIVE STUDY; RISK FACTOR; TREND STUDY; AGE; AGING; CLINICAL PRACTICE; ENGLAND; EPIDEMIOLOGY; MULTIVARIATE ANALYSIS; ODDS RATIO; ORAL DRUG ADMINISTRATION; RISK ASSESSMENT; STROKE; TIME FACTOR; TREATMENT OUTCOME; VERY ELDERLY;

ADMINISTRATION, ORAL; AGE FACTORS; AGED, 80 AND OVER; AGING; ANTICOAGULANTS; ATRIAL FIBRILLATION; ENGLAND; FEMALE; FIBRINOLYTIC AGENTS; GENERAL PRACTICE; HUMANS; MALE; MULTIVARIATE ANALYSIS; ODDS RATIO; PLATELET AGGREGATION INHIBITORS; PRACTICE PATTERNS, PHYSICIANS'; RISK ASSESSMENT; RISK FACTORS; STROKE; TIME FACTORS; TREATMENT OUTCOME;

EID: 84940654120     PISSN: 00020729     EISSN: 14682834     Source Type: Journal    
DOI: 10.1093/ageing/afv071     Document Type: Article

References (24)

1. Wolf PA, Abbott RD, Kannel WB. Atrial fibrillation as an independent risk factor for stroke: the Framingham study. Stroke 1991; 22: 983-8.
2. The Stroke Risk in Atrial Fibrillation Working Group. Independent predictors for stroke in patients with atrial fibrillation. Neurology 2007; 69: 546-54.
3. Marinigh R, Lip GYH, Fiotti N, Giansante C, Lane DA. Age as a risk factor for stroke in atrial fibrillation patients. J Am Coll Cardiol 2010; 56: 827-37.
4. Van Walraven C, Hart RG, Connolly S et al. Effect of age on stroke prevention therapy in patients with atrial fibrillation: the stroke prevenion investgators. Stroke 2009; 40: 1410-6.
5. Mant J, Hobbs FDR, Fletcher K et al. BAFTA Investigators, Midland Research Practices Network (MidReC). Warfarin versus aspirin for stroke prevention in an elderly community population with atrial fibrillation (the Birminigham Atrial Fibrillation Treatment of the Aged Study, BAFTA): a randomized controlled trial. Lancet 2007; 370: 493-503.
6. Singer DE, Chang Y, Fang MC et al. The net clinical enefit of warfarin anticoagulation in atrial fibrillation. Ann Intern Med 2009; 151: 297-305.
7. Friberg L, Hammar N, Ringh M, Pettersson H, Rosenqvist M. Stroke prophylaxis in atrial fibrillation: who gets it and who does not? Report from the Stockholm Cohort-study on Atrial Fibrillation (SCAF-study). Eur Heart J 2006; 26: 1954-64.
8. Sandhu RK, Bakal JA, Ezekowitz JA, McAlister FA. Risk stratification schemes, anticoagulation use and outcomes: the risk-treatment paradox in patients with newly diagnosed nonvalvular atrial fibrillation. Heart 2011; 97: 2046-50.
9. Cowan C, Healicon R, Robson I et al. The use of anticoagulants in the management of atrial fibrillation among general practices in England. Heart 2013; 99: 1166-72.
10. Camm AJ, Lip GY, De Caterina R et al. 2012 focused update of the ESC Guidelines for the management of atrial fibrillation: an update of the 2010 ESC Guidelines for the management of atrial fibrillation. Eur Heart J 2012; 33: 2719-47.
11. National Clinical Guideline Centre. Atrial Fibrillation: The Management of Atrial Fibrillation. National Institute for Health and Care Excellence, 2014. http://www.nice.org.uk/guidance/cg180/resources/guidance-atrial-fibrillation-the-managementof-atrial-fibrillation-pdf(23 November 2014, date last accessed).
12. You JJ, Singer DE, Howard PA et al. Antithrombotic therapy for atrial fibrillation: antithrombotic therapy and prevention of thrombosis, 9th ed: American College of Chest Physicians Evidence-Based Clinical Practice Guidelines. Chest 2012; 141: e531S-75S.
13. DeWilde S, Carey IM, Emmas C, Richards N, Cook DG. Trends in the prevalence of diagnosed atrial fibrillation, its treatment with anticoagulation and predictors of such treatment in UK primary care. Heart 2006; 92: 1064-70.
14. Gallagher AM, Riebrock S, Plumb J, Van Staa TP. Initiation and persistence of warfarin or aspirin in patients with initiation and persistence of warfarin or aspirin in patients with patients receive stroke prophylaxis? J Thromb Haemostasis 2008; 6: 1500-6.
15. UK Office for National Statistics. http://www.ons.gov.uk/ons/ dcp171778_357100.pdf (23 November 2014, date last accessed).
16. Scowcroft ACE, Lee S, Mant J. Thromboprophylaxis of elderly patients with AF in the UK: an analysis using the General Practice Research Database (GPRD) 2000-2009. Heart 2013; 99: 127-32.
17. Halvorsen S, Atar D, Yang H et al. Efficacy and safety of apixaban compared with warfarin according to age for stroke prevention in atrial fibrillation: observations from the ARISTOTLE trial. Eur Heart J 2014; 35: 1864-72.
18. Halperin JL, Hankey GJ, Wojdyla DM et al. Efficacy and safety of rivaroxaban compared with warfarin among elderly patients with nonvalvular atrial fibrillation in the ROCKET AF trial. Circulation 2014; 130: 138-46.
19. Eikelboom JW, Wallentin L, Connolly SJ et al. Risk of bleeding with 2 doses of dabigatran compared with warfarin in older and younger patients with atrial fibrillation: an analysis of the randomized evaluation of long-term anticoagulant therapy (RE-LY) trial. Circulation 2011; 123: 2363-72.
20. Hylek EM, Evans-Molina C, Shea C, Henault LE, Regan S. Major hemorrhage and tolerability of warfarin in the first year of therapy among elderly patients with atrial fibrillation. Circulation 2007; 115: 2689-96.
21. Poli D, Antonucci E, Testa S et al. Bleeding risk in very old patients on vitamin K antagonist treatment. Results of a prospective collaborative study on elderly patients followed by Italian centres for anticoagulation. Circulation 2011; 124: 824-9.
22. Rash A, Downes T, Portner R, Yeo WW, Morgan N, Channer KS. A randomized controlled trial of warfarin versus aspirin for stroke prevention in octuagenarians with atrial fibrillation (WASPO). Age Ageing 2007; 36: 151-6.
23. Donzé J, Clair C, Hug B et al. Risk of falls and major bleeds in patients on oral anticoagulation therapy. Am J Med 2012; 125: 773-8.
24. Fang MC, Chang Y, Hylek EM et al. Advanced age, anticoagulation intensity, and risk for intracranial hemorrhage among patients taking warfarin for atrial fibrillation. Ann Intern Med 2004; 141: 745-52.